ABSTRACT
Objetivo desarrollar una app para su uso en la práctica asistencial, con información actualizada y veraz sobre la manipulación de medicamentos en los pacientes con disfagia y otros problemas de deglución, así como su compatibilidad con alimentos y espesantes. Método el desarrollo de la app Deglufarm® se hizo con un proyecto de los grupos de trabajo CRONOS, Nutrición y Tecno de la Sociedad Española de Farmacia Hospitalaria. Se constituyó un grupo de farmacéuticos especialistas, de diferentes ámbitos de la atención al paciente con disfagia. La creación de Deglufarm® constó de varias etapas: selección de principios activos, revisión bibliográfica, elaboración de contenidos, diseño (se contactó con una empresa experta en diseño de apps), testing, lanzamiento, actualización de contenidos y seguimiento. Resultados Deglufarm® está disponible para Android e IOS gratuitamente desde julio de 2022. Ha sido testada entre los miembros del grupo investigador y colaboradores. En la actualidad se han revisado y registrado en Deglufarm® 540 monografías de principios activos. La primera versión está dirigida a profesionales sanitarios. Conclusiones Deglufarm® es una herramienta fácil y sencilla de consultar, con la evidencia más actual sobre la manipulación de los medicamentos que contiene. (AU)
Objective Develop an App to use in healthcare practice, with updated and accurate information on the handling of medications in patients with dysphagia or deglution disorders, as well as their compatibility with food and thickeners. Methods The development of the Deglufarm® App was based on the CRONOS, Nutrition and Techno working groups of the Sociedad Española de Farmacia Hospitalaria. A group of specialist pharmacists was created from different care areas for patients with dysphagia. The creation of Deglufarm® consisted of several stages: Selection of active drugs, literature review, content development, design (an expert company in App design was contacted), testing, launch, content update and follow-up. Results Deglufarm® is available for Android and IOS free of charge from July 2022. It has been tested among the members of the research group and collaborators, currently, 540 monographs of active drugs have been reviewed and registered in Deglufarm. The first version is aimed at healthcare professionals. Conclusions Deglufarm® is an easy tool to consult, with the most current evidence on handling the medicines it contains. (AU)
Subject(s)
Humans , Mobile Applications , Pharmaceutical Preparations/administration & dosage , Deglutition Disorders/drug therapyABSTRACT
OBJECTIVE: Develop an App to use in healthcare practice, with updated and accurate information on the handling of medications in patients with dysphagia or deglution disorders, as well as their compatibility with food and thickeners. METHODS: The development of the Deglufarm® App was based on the CRONOS, Nutrition and Techno working groups of the Sociedad Española de Farmacia Hospitalaria. A group of specialist pharmacists was created from different care areas for patients with dysphagia. The creation of Deglufarm® consisted of several stages: selection of active drugs, literature review, content development, design (an expert company in App design was contacted), testing, launch, content update and follow-up. RESULTS: Deglufarm® is available for Android and IOS free of charge from July 2022. It has been tested among the members of the research group and collaborators, Currently, 540 monographs of active drugs have been reviewed and registered in Deglufarm. The first version is aimed at healthcare professionals. CONCLUSIONS: Deglufarm® is an easy tool to consult, with the most current evidence on handling the medicines it contains.
Subject(s)
Deglutition Disorders , Mobile Applications , Humans , Deglutition Disorders/drug therapy , Pharmaceutical Preparations , Pharmacists , Health PersonnelABSTRACT
OBJECTIVE: Develop an App to use in healthcare practice, with updated and accurate information on the handling of medications in patients with dysphagia or deglution disorders, as well as their compatibility with food and thickeners. METHODS: The development of the Deglufarm® App was based on the CRONOS, Nutrition and Techno working groups of the Sociedad Española de Farmacia Hospitalaria. A group of specialist pharmacists was created from different care areas for patients with dysphagia. The creation of Deglufarm® consisted of several stages: Selection of active drugs, literature review, content development, design (an expert company in App design was contacted), testing, launch, content update and follow-up. RESULTS: Deglufarm® is available for Android and IOS free of charge from July 2022. It has been tested among the members of the research group and collaborators, currently, 540 monographs of active drugs have been reviewed and registered in Deglufarm. The first version is aimed at healthcare professionals. CONCLUSIONS: Deglufarm® is an easy tool to consult, with the most current evidence on handling the medicines it contains.
Subject(s)
Deglutition Disorders , Mobile Applications , Humans , Deglutition Disorders/drug therapy , Health Personnel , Pharmaceutical Preparations , PharmacistsABSTRACT
No disponible
Subject(s)
Humans , Male , Middle Aged , Atrial Flutter/chemically induced , Atrial Flutter/drug therapy , Antineoplastic Agents/adverse effects , Metoprolol/therapeutic use , Amiodarone/therapeutic use , Carcinoma, Renal Cell/drug therapy , Electrocardiography/methods , Cardiovascular Diseases/chemically induced , Cardiovascular Diseases/prevention & controlSubject(s)
Angiogenesis Inhibitors/adverse effects , Atrial Flutter/chemically induced , Pyrimidines/adverse effects , Sulfonamides/adverse effects , Angiogenesis Inhibitors/therapeutic use , Carcinoma, Renal Cell/complications , Carcinoma, Renal Cell/drug therapy , Electrocardiography , Fatal Outcome , Humans , Indazoles , Kidney Neoplasms/complications , Kidney Neoplasms/drug therapy , Male , Middle Aged , Pyrimidines/therapeutic use , Sarcoma/complications , Sarcoma/drug therapy , Sulfonamides/therapeutic useABSTRACT
No disponible
Subject(s)
Humans , Female , Aged, 80 and over , Sertraline/adverse effects , Lung Diseases, Interstitial/chemically induced , Depression/drug therapySubject(s)
Lung Diseases/chemically induced , Lung Diseases/therapy , Respiration Disorders/chemically induced , Respiration Disorders/therapy , Selective Serotonin Reuptake Inhibitors/adverse effects , Sertraline/adverse effects , Aged, 80 and over , Depression/complications , Depression/drug therapy , Female , Humans , Selective Serotonin Reuptake Inhibitors/therapeutic use , Sertraline/therapeutic useSubject(s)
Adenocarcinoma/complications , Antibodies, Monoclonal/adverse effects , Antineoplastic Agents/adverse effects , Splenic Rupture/chemically induced , Stomach Neoplasms/complications , Adenocarcinoma/drug therapy , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal, Humanized , Antineoplastic Agents/therapeutic use , Humans , Male , Middle Aged , Splenic Rupture/diagnostic imaging , Splenic Rupture/therapy , Stomach Neoplasms/drug therapy , RamucirumabABSTRACT
No disponible
Subject(s)
Humans , Male , Middle Aged , Splenic Rupture/chemically induced , Stomach Neoplasms/complications , Antineoplastic Agents/adverse effects , Stomach Neoplasms/drug therapyABSTRACT
No disponible
Subject(s)
Humans , Male , Middle Aged , Diarrhea/chemically induced , Phosphatidylinositols/antagonists & inhibitors , Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy , Rituximab/therapeutic use , Withholding TreatmentSubject(s)
Diarrhea/chemically induced , Phosphoinositide-3 Kinase Inhibitors , Protein Kinase Inhibitors/adverse effects , Purines/adverse effects , Quinazolinones/adverse effects , Humans , Leukemia, B-Cell/complications , Leukemia, B-Cell/drug therapy , Male , Middle Aged , Protein Kinase Inhibitors/therapeutic use , Purines/therapeutic use , Quinazolinones/therapeutic useSubject(s)
Antidepressive Agents/adverse effects , Long QT Syndrome/chemically induced , Venlafaxine Hydrochloride/adverse effects , Acute Coronary Syndrome/diagnosis , Acute Coronary Syndrome/drug therapy , Adult , Cardiovascular Agents/therapeutic use , Diagnostic Errors , Drug Substitution , Electrocardiography , Humans , Long QT Syndrome/diagnosis , Male , Sertraline/therapeutic use , Sodium Channel Blockers/adverse effects , Tachycardia, Sinus/chemically induced , Tachycardia, Sinus/diagnosis , Tachycardia, Sinus/drug therapyABSTRACT
No disponible